Zwager, Mieke C.
Bense, Rico
Waaijer, Stijn
Qiu, Si-Qi
Timmer-Bosscha, Hetty
de Vries, Elisabeth G. E.
Schröder, Carolien P.
van der Vegt, Bert http://orcid.org/0000-0002-2613-1506
Funding for this research was provided by:
KWF Kankerbestrijding (RUG2010-4739)
Van der Meer-Boerema Foundation (-)
Article History
Received: 1 December 2022
Accepted: 29 December 2022
First Online: 9 January 2023
Declarations
:
: BvdV reports honoraria received by UMCG for expertise or scientific advisory board/consultancy (on request): Visiopharm, Philips, MSD/Merck, Daiichi Sankyo/AstraZenica; Speaker’s fee from Visiopharm, Diaceutics, MSD/Merck. All unrelated to the current publication. EGEdV reports institutional financial support for advisory boards/consultancy from NSABP, Daiichi Sankyo and Crescendo Biologics, and institutional financial support for clinical trials or contracted research grants from Amgen, Genentech, Roche, CytomX, G1 Therapeutics, Bayer, Synthon, Servier, Regeneron, Crescendo Biologics, GE Healthcare and AstraZeneca. Regarding non-financial interests, including non-remunerated activities and public positions, EGEdV reports being a member of the ESMO-MCBS working party, chair of the ESMO Cancer Medicines Working Group, co-chair of the RECIST committee, and member of expert panel for selection of Essential Medicine List WHO. The other authors report no competing interests.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Local Ethics Review Board Pathology non-WMO studies (UMCG research register number 201900243, approved on 18-8-2020).
: Informed consent was not required according to the Dutch Law for Medical Research and institutional guidelines.
: Not applicable.